Biologics and Biosimilars Market

The future of medicine is large molecule. Biologics, which include monoclonal antibodies, recombinant proteins, and cell and gene therapies, are the fastest growing and most profitable segment of the global pharmaceutical market. They target complex diseases like cancer, rheumatoid arthritis, and autoimmune conditions with a specificity that small molecule pills cannot match. As patents on blockbuster biologics expire, the global biosimilars market (the generic equivalent of biologics) is opening up. This requires immense capital investment in mammalian cell culture facilities and deep analytical characterisation capabilities, a space where Indian biotech firms are increasingly making their mark.

What Numbro covers:

Global pipeline tracking of patented biologics and upcoming biosimilar opportunities based on patent expiry cliffs through 2030. Manufacturing capacity analysis for single use bioreactors versus traditional stainless steel systems. Regulatory pathway deep dive for biosimilar approval in the US (BPCIA) and EU, including interchangeability designation requirements. India ecosystem mapping of major biopharma players (Biocon Biologics, Dr. Reddy’s, Intas) and their global market access strategies.